HK59496A - Stabilized pharmaceutical compositions containing angiotens in-converting enzyme inhibitors - Google Patents

Stabilized pharmaceutical compositions containing angiotens in-converting enzyme inhibitors

Info

Publication number
HK59496A
HK59496A HK59496A HK59496A HK59496A HK 59496 A HK59496 A HK 59496A HK 59496 A HK59496 A HK 59496A HK 59496 A HK59496 A HK 59496A HK 59496 A HK59496 A HK 59496A
Authority
HK
Hong Kong
Prior art keywords
angiotens
pharmaceutical compositions
compositions containing
converting enzyme
enzyme inhibitors
Prior art date
Application number
HK59496A
Other languages
English (en)
Inventor
Michael Harris
Gerard Hokanson
Kuchi Murthy
Robert Reisch
Waldman Frank
Original Assignee
Parke Davis & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21785512&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK59496(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Parke Davis & Co filed Critical Parke Davis & Co
Publication of HK59496A publication Critical patent/HK59496A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Non-Silver Salt Photosensitive Materials And Non-Silver Salt Photography (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK59496A 1987-02-24 1996-04-03 Stabilized pharmaceutical compositions containing angiotens in-converting enzyme inhibitors HK59496A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/017,962 US4743450A (en) 1987-02-24 1987-02-24 Stabilized compositions

Publications (1)

Publication Number Publication Date
HK59496A true HK59496A (en) 1996-04-12

Family

ID=21785512

Family Applications (1)

Application Number Title Priority Date Filing Date
HK59496A HK59496A (en) 1987-02-24 1996-04-03 Stabilized pharmaceutical compositions containing angiotens in-converting enzyme inhibitors

Country Status (13)

Country Link
US (1) US4743450A (xx)
EP (1) EP0280999B1 (xx)
JP (1) JP2619904B2 (xx)
AT (1) ATE84210T1 (xx)
AU (1) AU597471B2 (xx)
CA (1) CA1300510C (xx)
DE (1) DE3877226T2 (xx)
DK (1) DK169593B1 (xx)
HK (1) HK59496A (xx)
IE (1) IE60931B1 (xx)
NZ (1) NZ223407A (xx)
PH (1) PH26279A (xx)
ZA (1) ZA88382B (xx)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3739690A1 (de) * 1987-11-24 1989-06-08 Hoechst Ag Stabilisierte arzneistoffe, verfahren zu ihrer herstellung sowie stabile arzneizubereitungen
IL88502A (en) * 1987-12-14 1993-04-04 Squibb & Sons Inc Pharmaceutical compositions containing an angiotensin converting enzyme inhibitor
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
HU222489B1 (hu) * 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
US6300361B1 (en) 1990-07-25 2001-10-09 Novartis Ag Stabilized pharmaceutical compositions comprising acid donors
US5292520A (en) * 1990-09-13 1994-03-08 Akzo N.V. Stabilized solid pharmaceutical composition containing acid addition salts of a basic drug and an alkaline stabilizer
DE69104453T2 (de) 1990-09-13 1995-03-16 Akzo Nv Stabilisierte feste chemische Zusammensetzungen.
US5238935A (en) * 1991-05-20 1993-08-24 Schering Corporation N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme A: cholesterol acyl transferase
US5124337A (en) * 1991-05-20 1992-06-23 Schering Corporation N-acyl-tetrahydroisoquinolines as inhibitors of acyl-coenzyme a:cholesterol acyl transferase
FR2665834B1 (fr) * 1991-07-24 2001-02-23 Sandoz Sa Composition pharmaceutique stabilisee par un donneur d'acide chlorhydrique, et sa preparation.
TW284688B (xx) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
SI9111842A (sl) * 1991-11-25 1998-04-30 Krka Stabilna formulacija soli enalaprila, postopek za njeno pripravo in njena uporaba
TW483763B (en) * 1994-09-02 2002-04-21 Astra Ab Pharmaceutical composition comprising of ramipril and dihydropyridine compound
US5573780A (en) * 1995-08-04 1996-11-12 Apotex Usa Inc. Stable solid formulation of enalapril salt and process for preparation thereof
US6296871B1 (en) 1998-04-12 2001-10-02 Ranbaxy Laboratories Limited Stable solid pharmaceutical compositions containing enalapril maleate
US6153223A (en) * 1998-06-05 2000-11-28 Watson Pharmaceuticals, Inc. Stabilized pharmaceutical compositions
HUP0102260A3 (en) * 1998-06-05 2002-12-28 Warner Lambert Co Stabilization of compositions containing ace inhibitors using magnesium oxide
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
US20030027837A1 (en) * 1998-12-08 2003-02-06 Sherman Bernard Charles Pharmaceutical compositions comprising quinapril magnesium
US6637359B1 (en) * 1998-12-15 2003-10-28 Maritrans Inc. System and method for internally fitting a new inner hull to an existing outer hull to form a rebuilt double hull vessel
US6060461A (en) * 1999-02-08 2000-05-09 Drake; James Franklin Topically applied clotting material
MY121470A (en) * 1999-05-03 2006-01-28 Ranbaxy Lab Ltd Stable solid pharmaceutical compositions containing enalapril maleate
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
WO2001015674A2 (en) * 1999-08-30 2001-03-08 Aventis Pharma Deutschland Gmbh Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events
US6555551B1 (en) 1999-08-31 2003-04-29 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
US20030225124A1 (en) * 1999-08-31 2003-12-04 Spiridon Spireas Stable formulations of ACE inhibitors, and methods for preparation thereof
US6764694B1 (en) * 1999-08-31 2004-07-20 Mutual Pharmaceutical Co., Inc. Stable formulations of ACE inhibitors, and methods for preparation thereof
US20040157911A1 (en) * 1999-08-31 2004-08-12 Spiridon Spireas Storage-stable and bio-stable formulations of ace inhibitors, and methods for preparation thereof
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
CA2303481A1 (en) * 2000-04-05 2001-10-05 Bernard Charles Sherman Pharmaceutical compositions comprising moexipril magnesium
US6333332B1 (en) * 2000-08-25 2001-12-25 Impax Laboratories, Inc. Stabilized pharmaceutical compositions containing bupropion hydrochloride
TWI232102B (en) * 2001-07-17 2005-05-11 Shionogi & Co A pharmaceutical formulation for injection
US20040170689A1 (en) * 2001-11-09 2004-09-02 Odink Debra Alida Stabilized formulations comprising hydrolytically unstable compositions
AU2003235579A1 (en) * 2002-01-15 2003-07-30 Delta Hf. Formulations of quinapril and related ace inhibitors
US20050202081A1 (en) * 2002-01-15 2005-09-15 Deepak Bahl Stable pharmaceutical compositions comprising ace inhibitor(s)
US20030157165A1 (en) * 2002-02-01 2003-08-21 Sherman Bernard Charles Stable saccharide-free tablets comprising a salt of quinapril or moexipril
US20030215526A1 (en) * 2002-03-08 2003-11-20 Scott Stofik Stable formulations of angiotensin converting enzyme (ACE) inhibitors
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
CA2530788C (en) * 2003-06-26 2010-02-09 Teva Pharmaceutical Industries Ltd Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives
US6869963B2 (en) * 2003-07-11 2005-03-22 Sandoz Ag Stable pharmaceutical compositions containing an ACE inhibitor
WO2005027881A2 (en) * 2003-09-23 2005-03-31 Texcontor Etablissement Stable quinapril compositions
US20050181055A1 (en) * 2003-10-08 2005-08-18 Mathur Rajeev S. Pharmaceutical compositions of quinapril
AU2003300692A1 (en) * 2003-10-30 2005-05-19 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
US20080234353A1 (en) * 2004-03-24 2008-09-25 Reynir Eyjolfsson Formulations of Ramipril
ES2603856T3 (es) * 2004-03-29 2017-03-01 Les Laboratoires Servier Procedimiento para preparar una composición farmacéutica sólida
SI21800A (sl) 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Nov postopek sinteze perindoprila
DE102004054054A1 (de) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
JP2008024592A (ja) * 2005-01-28 2008-02-07 Taisho Pharmaceut Co Ltd シアノピロリジン誘導体含有固形製剤用組成物、それを含有する固形製剤及びその製造方法
GR1006875B (el) * 2005-06-30 2010-07-12 "Φαρματεν" Φαρμακευτικη Βιομηχανικη Εμπορικη Α.Ε., Βελτιωμενες φαρμακευτικες συνθεσεις περιεχουσες αναστολεις του μετατρεπτικου ενζυμου αγγειοτενσινης και μεθοδοι παρασκευης αυτων.
GB0518129D0 (en) * 2005-09-06 2005-10-12 Arrow Int Ltd Ramipril formulation
GB2431579A (en) * 2005-10-28 2007-05-02 Arrow Int Ltd Ramipril formulations
US20070098782A1 (en) * 2005-10-28 2007-05-03 Selamine Limited Ramipril Formulation
PL1948224T3 (pl) 2005-11-17 2014-10-31 Silverstone Pharma Est Trwały preparat amorficznych soli peryndoprylu, sposób ich wytwarzania, zwłaszcza wytwarzania w skali przemysłowej oraz ich zastosowanie w terapii nadciśnienia
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
US7943655B2 (en) * 2006-04-05 2011-05-17 Universitat Zurich Polymorphic and pseudopolymorphic forms of trandolaprilat, pharmaceutical compositions and methods for production and use
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
CN102838599A (zh) 2006-05-04 2012-12-26 贝林格尔.英格海姆国际有限公司 多晶型
US20100035955A1 (en) * 2006-06-30 2010-02-11 Panagiotis Keramidas Stabilised Composition Comprising ACE Inhibitors
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
NZ600126A (en) * 2007-08-17 2013-12-20 Boehringer Ingelheim Int Purine derivatives for use in the treatment of fap-related diseases
JP2009084242A (ja) * 2007-10-02 2009-04-23 Nichi-Iko Pharmaceutical Co Ltd 安定性に優れた塩酸テモカプリル錠剤
JP5113476B2 (ja) * 2007-10-09 2013-01-09 沢井製薬株式会社 保存安定性に優れた塩酸テモカプリルの錠剤
CN101854932A (zh) * 2007-11-07 2010-10-06 詹森药业有限公司 包含血管紧张素转化酶抑制剂和加压素受体拮抗剂的组合疗法
WO2009113081A1 (en) * 2008-03-10 2009-09-17 Lupin Limited Tris (hydroxymethyl ) amino methane salt of quinapril and ramipril
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
AU2009281122C1 (en) * 2008-08-15 2016-04-21 Boehringer Ingelheim International Gmbh Purin derivatives for use in the treatment of fab-related diseases
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
AU2009331471B2 (en) 2008-12-23 2015-09-03 Boehringer Ingelheim International Gmbh Salt forms of organic compound
AR074990A1 (es) 2009-01-07 2011-03-02 Boehringer Ingelheim Int Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
KR102668834B1 (ko) 2009-11-27 2024-05-24 베링거 인겔하임 인터내셔날 게엠베하 리나글립틴과 같은 ｄｐｐ－ｉｖ 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
ES2935300T3 (es) 2010-05-05 2023-03-03 Boehringer Ingelheim Int Combiterapia
EP2585051B2 (en) * 2010-06-23 2020-04-08 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical oral dosage forms comprising lercanidipine and enalapril and their pharmaceutically acceptable salts
KR20230051307A (ko) 2010-06-24 2023-04-17 베링거 인겔하임 인터내셔날 게엠베하 당뇨병 요법
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
EP2654729B1 (en) 2010-12-24 2016-05-04 KRKA, d.d., Novo mesto Homogenous pharmaceutical oral dosage forms comprising lercanidipine and enalapril or their pharmaceutically acceptable salts together with an organic acid
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
EA030121B1 (ru) 2011-07-15 2018-06-29 Бёрингер Ингельхайм Интернациональ Гмбх Замещенные хиназолины, их получение и их применение в фармацевтических композициях
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US8568747B1 (en) 2012-10-05 2013-10-29 Silvergate Pharmaceuticals, Inc. Enalapril compositions
PL227900B1 (pl) 2012-11-15 2018-01-31 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Kompozycja farmaceutyczna zawierająca inhibitor ACE i bloker kanałów wapniowych, sposób jej wytwarzania i jednostka dawkowania zawierająca tę kompozycję
US9937153B2 (en) 2013-08-30 2018-04-10 Merck Sharp & Dohme Ltd. Oral pharmaceutical formulation of omarigliptin
ES2950384T3 (es) 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
DK3193826T3 (en) 2014-07-31 2019-02-11 Pharmathen Sa ORODISPERSIBLE MOVIE COMPOSITION, INCLUDING ENALAPRIL FOR TREATMENT OF HYPERTENSION OF A PEDIATRIC POPULATION
SI3524595T1 (sl) 2014-08-28 2022-10-28 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistosti in postopek njegove proizvodnje
WO2016136745A1 (ja) 2015-02-25 2016-09-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 キノリン誘導体の苦味抑制方法
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CA2988707C (en) 2015-06-16 2023-10-10 Eisai R&D Management Co., Ltd. Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
WO2017077425A1 (en) 2015-11-07 2017-05-11 Ftf Pharma Private Limited Oral solution of ace inhibitors
US9669008B1 (en) 2016-03-18 2017-06-06 Silvergate Pharmaceuticals, Inc. Enalapril formulations
EP4233840A3 (en) 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422176A (en) * 1973-05-05 1976-01-21 Beecham Group Ltd Pharmaceutical tablets
US4255413A (en) * 1979-10-01 1981-03-10 Smithkline Corporation Gelatin capsule dosage unit containing triamterene
ATE25244T1 (de) * 1981-12-29 1987-02-15 Hoechst Ag Neue derivate bicyclischer aminosaeuren, verfahren zu ihrer herstellung, diese enthaltende mittel und deren verwendung sowie neue bicyclische aminosaeuren als zwischenstufen und verfahren zu deren herstellung.
US4584299A (en) * 1984-05-21 1986-04-22 Warner-Lambert Company Method of treating heart failure and medicaments therefor
US4656188A (en) * 1985-10-09 1987-04-07 Merck & Co., Inc. Ace inhibitors in macular degeneration
JPH06104680B2 (ja) * 1985-11-13 1994-12-21 株式会社大塚製薬工場 プロリン誘導体
DE3610391A1 (de) * 1986-03-27 1987-10-08 Hoechst Ag Verbindungen mit nootroper wirkung, diese enthaltende mittel und deren verwendung bei der behandlung und prophylaxe cognitiver dysfunktionen

Also Published As

Publication number Publication date
JPS63225322A (ja) 1988-09-20
NZ223407A (en) 1989-08-29
EP0280999A3 (en) 1988-11-17
AU597471B2 (en) 1990-05-31
US4743450A (en) 1988-05-10
EP0280999B1 (en) 1993-01-07
DE3877226T2 (de) 1993-04-29
PH26279A (en) 1992-04-10
DK94088A (da) 1988-08-25
ZA88382B (en) 1989-09-27
IE60931B1 (en) 1994-09-07
JP2619904B2 (ja) 1997-06-11
ATE84210T1 (de) 1993-01-15
EP0280999A2 (en) 1988-09-07
DK169593B1 (da) 1994-12-19
IE880142L (en) 1988-08-24
DK94088D0 (da) 1988-02-23
CA1300510C (en) 1992-05-12
AU1130588A (en) 1988-08-25
DE3877226D1 (de) 1993-02-18

Similar Documents

Publication Publication Date Title
HK59496A (en) Stabilized pharmaceutical compositions containing angiotens in-converting enzyme inhibitors
AU7939787A (en) Drug compositions stabilized against oxidation
AU7927487A (en) Stabilized drug compositions
HK99593A (en) Pharmaceutical compositions containing a dideoxynucleoside
AU5122885A (en) Enzyme modification of tobacco
AU2020888A (en) Morpholinohexose reductone as an oxygen scavenger
AU1376588A (en) Derivative of a fibrinolytic enzyme
IL87327A0 (en) Aqueous enzyme compositions comprising proteolytic inhibitors as stabilizers
EP0297816A3 (en) Homocyclostatine and cyclostatine containing polypeptides as antihypertensive agents
AU1732888A (en) Stable 5-fluorouracil compositions
AU1077688A (en) Modified fibrinolytic enzymes
AU1203888A (en) Treatment of timber
AU3031689A (en) Tris-kringle plasminogen activator with novel k2 insert

Legal Events

Date Code Title Description
PF Patent in force
PE Patent expired

Effective date: 20080222